HDS 029

Cat. No. 2646

HDS 029 C17H11ClFN5O [881001-19-0]

Price and Availability

For HDS 029 pricing & availability please select your country from the drop down menu:
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Chemical Name: N-(4-[(-3-Chloro-4-fluorophenyl)amino]pyrido[3,4-d]pyrimidin-6-yl-2-butynamide

Biological Activity

Potent inhibitor of the ErbB receptor family (IC50 values are 0.3, 0.5 and 1.1 nM for ErbB1 (EGFR), ErbB4 and ErbB2 respectively). Inhibits EGF-induced erbB1 autophosphorylation in NIH3T3 cells and heregulin-stimulated ErbB autophosphorylation in MDA-MB-453 human breast carcinoma cells (IC50 values are 2.5 and 24 nM respectively).

Technical Data

Soluble to 25 mM in DMSO
>97 %
Store at -20°C


Other Information

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch
Safety Data Sheet: View Safety Data Sheet


Klutchko et al (2006) Tyrosine kinase inhibitors. 19. 6-alkynamides of 4-anilinoquinazolines and 4-aniliopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors. J.Med.Chem. 49 1475. PMID: 16480284.

If you know of a relevant citation for this product please let us know.

Keywords: HDS 029, supplier, Potent, inhibitors, ErbB, receptor, family, Epidermal, Growth, Factors, Receptors, Her, EGFR, Receptor, Tyrosine, Kinases, RTKs, HDS029

Quick Order

Find multiple products by catalog number

divider line

Kinases Product Listing

Kinases Product Listing

Highlights over 400 products for kinase research. Request a copy or view PDF today.

divider line

Kinase Inhibitor Toolbox

80 Kinase inhibitors
pre-dissolved in DMSO

Kinase Inhibitor Toolbox

Includes many of the latest kinase inhibitors to become commercially available. Covers a wide range of kinase targets including EGFR, MAPK and CDK.

divider line

VEGF Pathway & Anti-Angiogenic Therapy

Written by N. Ferrara & Y. Crawford

Angiogenesis Poster

A summary of antiangiogenic therapies targeting the VEGF pathway and the mechanisms of therapy resistance.

divider line

Therapeutic Strategies in Schizophrenia

Written by J. Lieberman

Schizophrenia Poster

'Schizophrenia - Emerging Targets and Therapeutic Strategies' provides a summary of the targets and pathways representing the most promising strategies to pursue for novel drug development.

divider line

New Product Guide


Highlights 130 new products added in the first half of 2015. View PDF today.

divider line

New Products in this Area

PF 06463922

High affinity and selective ALK and ROS1 inhibitor


Insulin degrading enzyme (IDE) inhibitor


Potent c-MET/ALK inhibitor

AC 710

Potent and selective PDGFR family inhibitor

SPP 86

Potent RET inhibitor

SGX 523

Selective and potent c-MET kinase inhibitor

NBI 31772

High affinity insulin-like growth factor-I binding protein IGFBP inhibitor

Sign-up for new product e-alerts
divider line

Bio-Techne Events


Neuroscience 2015

October 17-21, 2015

Chicago, IL